Esophageal cancer is an aggressive and deadly form of cancer. There are two major subtypes: esophageal adenocarcinoma and esophageal squamous cell carcinoma. In the United States, the epidemiology of these two subtypes is evolving, and the May Lab studies them separately as they have many distinct risk factors.
Our team uses national data and cancer registry data to study national trends in esophageal cancer incidence, mortality, survival, and disease stage at presentation in the United States.
Our team also examines national racial and ethnic disparities in esophageal cancer incidence and outcomes to better understand how all individuals, regardless of background, can have the best possible outcomes after a diagnosis of esophageal cancer.
Future studies will aim to understand how to improve the care and well-being of patients with a diagnosis of esophageal cancer at UCLA Health. We are also interested in finding ways to improve the delivery of healthcare to patients with this disease in the greater Los Angeles area.
- Kevin Ghassemi, MD, Health Sciences Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA
- V. Raman Muthusamy, MD, MAS, Professor of Clinical Medicine, David Geffen School of Medicine at UCLA
Publications - Full List of May Lab Publications Here
- Corona E, Yang L, Esrailian E, Ghassemi KA, Conklin JL, May FP. Trends in Esophageal Cancer Mortality and Stage at Diagnosis by Race and Ethnicity in the United States. Cancer Causes Control. 2021 Aug;32(8):883-894. doi: 10.1007/s10552-021-01443-z. Epub 2021 May 18. PMID: 34003396; PMCID: PMC8236464
- Mafi JN, May FP, Kahn KL, Chong M, Corona E, Yang L, Mongare MM, Nair V, Reynolds C, Gupta R, Damberg CL, Esrailian E, Sarkisian C. Low-Value Proton Pump Inhibitor Prescriptions Among Older Adults at a Large Academic Health System. J Am Geriatr Soc. 2019 Dec;67(12):2600-2604. doi: 10.1111/jgs.16117. Epub 2019 Sep 5. PMID: 31486549; PMCID: PMC6952216